 | Up a level |
Schmitt, Andreas Michael; Walter, Martin; Herbrand, Amanda Katherina; Jörger, Markus; Moffa, Giusi; Novak, Urban; Hemkens, Lars; Kasenda, Benjamin (2022). Characteristics and survival of patients with cancer with intended off-label use-a cohort study. BMJ open, 12(5), e060453. BMJ Publishing Group 10.1136/bmjopen-2021-060453
Begré, Ursina B M; Jörger, Markus; Aebi, Stefan; Amstutz, Ursula; Largiadèr, Carlo R (2022). Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland. Frontiers in Pharmacology, 13, p. 885259. Frontiers 10.3389/fphar.2022.885259
Ribi, Karin; Bernhard, Jürg; Schuller, Jan C; Weder, Walter; Bodis, Stephan; Jörger, Markus; Betticher, Daniel; Schmid, Ralph A; Stupp, Roger; Ris, Hans-Beat; Stahel, Rolf A (2008). Individual versus standard quality of life assessment in a phase II clinical trial in mesothelioma patients: feasibility and responsiveness to clinical changes. Lung cancer, 61(3), pp. 398-404. Amsterdam: Elsevier 10.1016/j.lungcan.2008.01.013
